Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
In addition to providing mechanistic insights of cancer-related splicing dysregulation, this study establishes RBM4 as a tumor suppressor with therapeutic potential and clinical values as a prognostic factor.
|
25203323 |
2014 |
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
A xenograft tumor model was used to assess whether RBM4 inhibits GC growth in vivo.
|
31145716 |
2019 |
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
We show that TEAD4, the transcription factor that mediates Hippo-YAP signalling, undergoes alternative splicing facilitated by the tumour suppressor RBM4, producing a truncated isoform, TEAD4-S, which lacks an N-terminal DNA-binding domain, but maintains YAP interaction domain.
|
27291620 |
2016 |
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The alternative splicing imbalance of CoAA and RBM4, because of loss of their common enhancer in cancer, may deregulate stem/progenitor cell differentiation.
|
19416963 |
2009 |
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
RBM4 inhibits cancer cell growth and migration by regulating cancer-associated gene splicing.
|
25367940 |
2014 |
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
RBM4 cDNA probing of a cancer cDNA array involving 18 different tumor types from 13 different tissues and matching normal tissue found overexpression of RBM4 mRNA (p<0.01) in cervical, breast, lung, colon, ovarian and rectal cancers.
|
26898347 |
2016 |
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
RBM4 cDNA probing of a cancer cDNA array involving 18 different tumor types from 13 different tissues and matching normal tissue found overexpression of RBM4 mRNA (p<0.01) in cervical, breast, lung, colon, ovarian and rectal cancers.
|
26898347 |
2016 |
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
RBM4 inhibits cancer cell growth and migration by regulating cancer-associated gene splicing.
|
25367940 |
2014 |
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
The alternative splicing imbalance of CoAA and RBM4, because of loss of their common enhancer in cancer, may deregulate stem/progenitor cell differentiation.
|
19416963 |
2009 |
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
RNA-binding motif 4 (RBM4) has been reported to play an important role in many human tumors such as lung cancer, breast cancer, ovarian cancer and gastric cancer by regulating alternative splicing and messenger RNA (mRNA) translation.
|
28138257 |
2017 |
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
A xenograft tumor model was used to assess whether RBM4 inhibits GC growth in vivo.
|
31145716 |
2019 |
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
RNA-binding motif 4 (RBM4) has been reported to play an important role in many human tumors such as lung cancer, breast cancer, ovarian cancer and gastric cancer by regulating alternative splicing and messenger RNA (mRNA) translation.
|
28138257 |
2017 |
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
A xenograft tumor model was used to assess whether RBM4 inhibits GC growth in vivo.
|
31145716 |
2019 |
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
RNA-binding motif 4 (RBM4) has been reported to play an important role in many human tumors such as lung cancer, breast cancer, ovarian cancer and gastric cancer by regulating alternative splicing and messenger RNA (mRNA) translation.
|
28138257 |
2017 |
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events.
|
25140042 |
2014 |
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
RNA-Binding Motif 4 (RBM4) Suppresses Tumor Growth and Metastasis in Human Gastric Cancer.
|
31145716 |
2019 |
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These findings suggest that RBM4 is a new biomarker in gastric cancer, as the reduced expression of this protein is correlated with poor differentiation, lymph node status and distant metastasis.
|
27324405 |
2016 |
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
RBM4-regulated alternative splicing suppresses tumorigenesis.
|
25367940 |
2014 |
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These results constitute a mechanistic understanding of RBM4 on repressing the carcinogenesis of colorectal cells.
|
26506517 |
2015 |
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events.
|
25140042 |
2014 |
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
RNA-binding motif 4 (RBM4) has been reported to play an important role in many human tumors such as lung cancer, breast cancer, ovarian cancer and gastric cancer by regulating alternative splicing and messenger RNA (mRNA) translation.
|
28138257 |
2017 |
Down Syndrome
|
0.010 |
Biomarker
|
disease |
LHGDN |
Manifold decreased protein levels of matrin 3, reduced motor protein HMP and hlark in fetal Down's syndrome brain.
|
12469345 |
2002 |
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In situ hybridization and RNA immunoprecipitation assays demonstrated that TPM1-AS was located in the nucleus and interacted with RNA-binding motif protein 4 (RBM4) in human esophageal cancer cells.
|
28754317 |
2017 |
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
(Optimizing Linkage and Retention to Hypertension Care in Rural Kenya [LARK]; NCT01844596).
|
31487546 |
2019 |
Esophageal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In situ hybridization and RNA immunoprecipitation assays demonstrated that TPM1-AS was located in the nucleus and interacted with RNA-binding motif protein 4 (RBM4) in human esophageal cancer cells.
|
28754317 |
2017 |